



IFW
#

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Kieko MORITA

Confirmation No.: 5419

Serial Number: 10/665,117

Group Art Unit: 1616

Filed: September 22, 2003

Examiner: JONES, DAMERON LEVEST

For: DIAGNOSIS AND TREATMENT OF DISORDERS USING AN ALTERNATIVE
GLUCOSE PATHWAY

Atty. Docket No.: 030096A
Customer No.: 38834

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

December 1, 2004

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. A copy of each document is attached, except a US patent.

This Information Disclosure Statement is being submitted after issuance of a first official action on the merits and expiration of the three month period following the filing date or the entry of the national stage for the above-captioned application, but prior to issuance of either a final official action or a Notice of Allowance. A check is attached hereto which covers the \$180.00 fee set forth in 37 CFR § 1.17(p).


The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) concerning the PTO duty to consider and use any such information. It is respectfully requested

that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

The Commissioner is hereby authorized to charge any additional fee (or credit any overpayment) associated with this statement to our Deposit Account No. 50-2866.

Respectfully submitted,


WESTERMAN, HATTORI, DANIELS & ADRIAN, LLP


Nicolas E. Seckel
Attorney for Applicant
Reg. No. 44,373

Atty. Docket No. **030096A**
1725 K Street, N.W., Suite 1000
Washington, DC 20006
Tel: (202) 659-2930
Fax: (202) 887-0357

NES/ya

Enclosure: PTO-1449 and 8 References



INFORMATION DISCLOSURE STATEMENT PTO-1449	Atty. Docket No. 030096A	Serial No. 10/665,117
	Applicant(s): Kieko MORITA	
	Filing Date: September 22, 2003	Group Art Unit: 1616

U.S. PATENT DOCUMENTS

Examiner Initial		Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
	AA	6,620,802	Schatzberg et al.	09/16/2003	514	178	11/20/2000
	AB						

OTHER DOCUMENTS

_____	AC	Joseph K. Belanoff et al., "Slowing the Progression of Cognitive Decline in Alzheimer's Disease Using Mifepristone", <i>Journal of Molecular Neuroscience</i> , Vol. 19, 2002, Pages 201-206
_____	AD	Linda E. Carlson et al., "Relationships between Dehydroepiandrosterone Sulfate (DHEAS) and Cortisol (CRT) Plasma Levels and Everyday Memory in Alzheimer's Disease Patients Compared to Healthy Controls", <i>Hormones and Behavior</i> 35, 1999, Pages 254-263
_____	AE	Michael T. Falduto et al., "Role of Apolipoprotein E in Neurobiology and the Pathogenesis of Alzheimer's Disease", <i>Pharmacological Treatment of Alzheimer's Disease</i> , 1997 Chapter 12, Pages 287-307
_____	AF	Suzanne Craft, PhD et al., "Enhancement of Memory in Alzheimer Disease With Insulin and Somatostatin, but Not Glucose", <i>Arch Gen Psychiatry</i> Vol. 56 Dec. 1999, Pages 1135-1140
_____	AG	Segal MB., "Transport of Nutrients Across the Choroid Plexus", <i>Microsc Res Tech</i> , 2001, 52(1): 38-48, National Library of Medicine (PubMed, Abstract only)
_____	AH	Sommer JB et al., "Does lumbar cerebrospinal fluid reflect ventricular cerebrospinal fluid? A prospective study in patients with external ventricular drainage", <i>Eur Neurol</i> , 2002, 47(4): 224-32, National Library of Medicine (PubMed, Abstract only)
_____	AI	"Insulin, Neurogenetics and Memory in Alzheimer's Disease", <i>Clinical Trials.gov.</i> , Department of Veterans Affairs Medical Research Service
_____	AJ	"The Evaluation and Follow-up of Patients with Memory Disorder and Normal Volunteers", <i>Clinical Trials.gov.</i> , National Institute of Mental Health
Examiner		Date Considered